Xtant Medical

Xtant Medical Receives 510k Clearance for Expanded Indications of Irix-A

BELGRADE, Mont., Sept. 12, 2017 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that the U.S. Food and Drug Administration (FDA) has cleared product line extensions for the Irix-A interbody spacer.  The clearance provides for the addition of three additional size configurations for an expanded market opportunity, and importantly, for use with allograft.  This clearance is the second received during this quarter, and continues to strengthen Xtant Medical’s focus in providing a more comprehensive portfolio focused on regenerative care for the patient. Xtant Medical’s Ir…